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cation of sufficient time to respond to patients enquiries, consultations (about
patient’s disease, non-medical treatments, herbal medicines and supplements),
arrangement of service stages, honesty in delivery of scarce medicines, waiting
time, compliance of number and type of dispensed items with physician prescrip-
tion, convenience of pharmacy’s lobby space and suitable physical space for com-
munication with pharmacy staff. In addition, according to the result of the Fried-
man test, the most important issue for patients in the study was observation of
courtesy and respect by pharmacy staff. Overall satisfaction measured by weighted
values (based on priorities identified by participants) of three components of sat-
isfaction (physical space, service quality and staff behavior) was statistically dif-
ferent from satisfaction measured based on common method (3.48 vs. 3.40,
pvalue0.05). CONCLUSIONS: Pharmacy customers expect pharmacists to be more
involved in providing advice. Also it seems that improvement in design of pharmacies
physical space including allocation of an appropriate space for patients to talk with
pharmacy staff, specially pharmacist, can increase customer’s satisfaction. Observing
customers’ priorities may have an important influence on interpretation of the results
of satisfaction studies and, therefore, on the selection of interventions.
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OBJECTIVES: Given the financial crisis-driven budget cuts and the experienced
shortages in nursing stuff, this study aims to identify the factors that have contrib-
uted to nurses shortages, the optimum size of nursing stuff, the potential improve-
ment of nurses skills and role and the more effective measures to cope with the
current circumstances. METHODS: Experts from the fields of nursing and hospital
management were invited to participate in an expert panel and asked to provide
their opinion on the issues concerned with the objectives of the study. RESULTS:Of
the 32 experts invited 20 (62.5%) accepted to participate. The majority of the pan-
elists argued that the main reasons of nurses’ shortages are the lack of workforce
planning and the undersupply of nurses. Experts supported that nursing personnel
should at least triple (10.5 nurses/1000 population and 2.5 nurses/hospital bed) and
the nurses-doctor ratio should change from 0.61 nurses/doctor to 3 - 4 nurse/
doctor. Most of the experts argued that more nurses should be university graduates
and continuing education programs should be introduced. The substitution of doc-
tors’ services from nurses was widely accepted and argued that nurses’ role can be
expanded to prescribing, to the provision of preventive services, to the manage-
ment of chronic condition patients and to diagnostic tests interpretation. Finally, in
light of reduced health care budgets it was argued that shortages-driven issues
could be partially addressed by redistributing the existing personnel according to
population and hospitals’ needs. CONCLUSIONS: The measures suggested for the
improvement of nursing services quantity and quality may obscure in the con-
straints imposed by the current financial crisis. Redistributing the existing person-
nel can only provide a temporary solution. However, this study stresses the need
for an effective workforce planning in order for the health system to guarantee an
adequate level of services and equity in access, in times of reduced budgets.
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OBJECTIVES:This project evaluates the patients’ perception about Shared Decision
Making in primary attention in a single city. Also identify potential barriers and
facilitators for the shared decision making in the clinical practice. METHODS: It is
a quantitative study. All patients registered for family health care were invited. A
questionnaire covering demographic data, multiprofessional team, knowledge of
the health-illness and models of patient-physician relationship was developed and
validated through a previous pilot study. Statistical analysis was performed
through descriptive techniques and multiple correspondence analysis (to test as-
sociations among the categories).RESULTS:We interviewed 278 patients, 50% Cau-
casian, 79% female, 24% between 20 and 29 years and 42% with incomplete primary
education. Fourt-one percent are unemployed and have income between one and
two minimum wages. Of them, 78% and 78.4% consider the multidisciplinary work
very important and its inclusion in the process of treatment, respectively; 71.58%
prefer to decide the treatment with the doctor. Most users could not differ types of
patient-physician relationship, as paternalistic, shared and informed decisions. A
correspondence analysis plot was used to illustrate similarity of multidisciplinary
team and shared decision making. Female, mestizo, and age between 30 and 39
years was associated with more willingness to share the decisions with the physi-
cian, according to correspondence plot analysis. There was no association between
comprehension, decision-making and having a chronic disease or not. The other
answers have no association with any category. CONCLUSIONS: This study dem-
onstrated that patients on primary care believe that a multi-professional team-
work is important to apply shared decision making on clinical practice. The com-
prehension about informed, shared and paternalistic decision-making is confused
for this sample. Comparative studies between primary care and specialties may
assist the implementation of shared decision making, considering peculiarities in
both kind of health care.
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OBJECTIVES: The minimal role of clinical pharmacists on the medical floors in
several health care institutions in Arab countries, had led to the concern of pre-
scription errors. The objectives of this study was to determine if the presence of a
clinical pharmacist could be cost beneficial when even limited to avoiding medi-
cation transcription errors and unnecessary medication use for the prophylaxis of
stress ulcer and deep venous thrombosis. METHODS: A total of 1672 medication
orders were reviewed to assess the prevalence and type of transcription errors for
255 patients in the internal medicine over a 6-month period between December
2011 and May 2012. Pharmacy interventions were documented by clinical phar-
macy students during clinical rounds to determine inappropriate medication use.
A cost benefit analysis of introducing a clinical pharmacist on the medical floor was
performed. RESULTS:A total of 389 (23.3%) transcription errors were identified and
classified as 1) failure to transcribe medications from charts into pharmacy orders
(39.58%); 2) error in transcribing medications into pharmacy order (33.67%); or 3)
errors in medication administrations to patients (26.71%). The benefits of introduc-
ing a clinical pharmacist on the medical floor originate from the anticipated reduc-
tion of the losses caused by transcription errors, decreased length of hospitaliza-
tion stay, and reducing unnecessary medication use where a total of $49,885.5
would be saved which is almost three times the annual salary of a junior pharma-
cist in Lebanon, and a net benefit of $13,885.5 could be obtained. CONCLUSIONS:
The implementation of clinical pharmacy in Lebanese health care institutions is
needed to optimize healthc are clinical outcomes and subsequently minimizing
medication errors and economical burdens.
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OBJECTIVES: As payer decisions become increasingly evidence based, a key ques-
tion is whether payer on national/regional level are impacted by company percep-
tions when assessing evidence and making decisions. To identify what perceptions
payers have, if and how these impact their decisions and what differences exist
across stakeholders and companies, we analysed unprompted expressions of per-
ceptions obtained from interviews performed with national/regional payers.
METHODS:We analysed 543 national/regional payer interviews, performed for 100
projects by IMSCG 2008-2011 in Europe, including 900 quotes with unprompted
expressions compressed in 1900 buzz-words. Interviews were screened for quotes
reflecting perceptions of pharma unrelated to research objectives. Only un-
prompted expressions were extracted and buzz-words created that compressed
expressed perceptions into single words/phrases. Half of the quotes expressed
perceptions of specific companies. Analysis of the impact of perception on payer
decisions was based on 5% of overall quotes containing that link. Buzz-words were
valued, ranked according to occurrence and categorized into perception causes
(reputation, interaction, employees, portfolio and research). Payers validated ap-
proach and outcomes. RESULTS: Perceptions are predominantly caused by com-
pany reputation and interaction, with national payers more influenced by reputa-
tion, regional by pharma interactions. Differences exist between portfolio versus
employee perception, the former predominant in national, the latter in regional
payers. While 60% of buzz-words were positive, results differ with national payers
being significantly more critical towards industry then regional. The industry per-
ception was more negative than perceptions expressed for individual companies.
Perceptions directly impacting payer decisions were all negatively motivated by
reputation, interactions and product perceptions (‘me-too’), predominantly im-
pacting access. CONCLUSIONS: Payers are influenced by company perceptions,
which impact their decisions. Negative industry perceptions can be changed by
companies; focus should be on national payers as regional have more positive
perceptions already. Changing negative perceptions of company reputation, col-
laboration experience and employees’ qualifications might avoid negative impact
on access decisions.
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OBJECTIVES: In light of the financial crisis, the largest social insurance funds were
merged. This study aims to investigate the possibilities of a monopsony and to
propose alternative methods for the new fund to allocate resources and to reim-
burse physicians. METHODS: A structured questionnaire concerned with the po-
tentials of the new initiative, the resource allocation method and the physicians’
reimbursement methods was constructed. An interdisciplinary expert panel was
assembled and asked to provide its opinion on the above issues. RESULTS: A total
of 66.7% of the experts supported the monopsonistic character of the fund unlike
33.3% who preferred a bilateral monopoly structure. However, expert’s opinion on
the potential of the fund to control expenditure and reduce cost of time and prices
was not clear, while the majority argued that the fund can hardly guarantee ade-
quate quality services. 68.2% agreed on the introduction of regional global budgets
and the majority argued that the parameters to calculate the budget should be the
region’s population, the female, the birth, the elderly and the chronic condition
patient rates and the standard mortality ratio. The introduction of an internal
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market and capitation reimbursement for general practitioners and pediatricians
were widely accepted. Incentive payments for both the above specialties were
approved and determined according to the home visits for the pediatricians and
according to the number of the enrolled elderly and chronic condition patients, the
carry out of screening and the home visits for the general practitioners. Per-item
reimbursement for specialists was weakly supported. The introduction of an inter-
nal market along with global budgets and incentive payments was argued that
could control expenditure and supplier-induced demand, and improve equity in
access and outcomes. CONCLUSIONS: Experts argue that a public monopsony in
Greece can hardly guarantee efficiency and effectiveness, unless included in a
wider reform framework of prospective payments, market-like mechanisms and
financial incentives.
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OBJECTIVES: Early Access Programmes (EAPs) provide the possibility of making
medicines that address an unmet medical need available to patients before regu-
latory approval from the competent authorities. Market Access includes market
development activities and patient access strategy, EAPs can positively impact
both areas. The aim of this review is to consider, compile and describe the main
EAPs available in Non-European Countries.METHODS:We conducted a review and
performed a mapping of EAPs systems that exists in Europe. We searched existing
literature in Embase, National Health Systems Website, ISPOR conference websites
and Internet. In the countries where information were more scattered we directly
contacted regulatory agencies and clinicians familiar with the local EAP regula-
tions and practices.RESULTS:We described the practical implications surrounding
the regulatory framework for EAPs, the key stakeholders involved in EAP decision-
making and administration, the timelines for EAPs approval, and the key factors for
success. Many countries do not have an EAP in place and compassionate use is the
only route to market for unregistered or investigational products. This is the case
for Russia, Turkey, South Korea, Israel, India, and Brazil. The markets where EAP
are more developed and sales are possible are: South Africa, Canada and Australia.
CONCLUSIONS: This project made specific recommendations on the most favour-
able countries, based on the ease of setting up such a programme and the potential
revenue that could result.
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OBJECTIVES: The national government is repositioning the Community Pharma-
cies (CP) in the national health service, through definition of different: mix of ser-
vices, relation with other health care actors, and range of objectives to achieve.
Considering the contextual factors, the paper aims at analyzing the managerial
implication for CP. For this purpose the CPs’ director strategic attitude and the
structure of the information system are investigated. METHODS: The paper is
based on literature review and on a survey conducted among a national sample of
695 community pharmacies (CP). Data were collected through a questionnaire or-
ganized in both open questions and closed questions (Likert scale 1-7). Data were
analyzed according to descriptive statistics to support the qualitative study ap-
proach. The SPSS program was used. RESULTS: Respondents have limited aware-
ness of the different actions that the national and regional contexts implement
regard to the CP. Although, the mix of services provided is heterogeneous and not
widely consistent with the aims of the government reform (2009 law decree), there
is a positive willingness to extent the professional role. Increasing the mix of ser-
vices provided is perceived a strategic action (m5,09), services are delivered even
if the contribution to the CP’s revenues is very low (m2,62). The information
system allows the monitoring of the overall financial results (m5,33), while its
relevance decreases with regard to the CP’s cost structure (m4,5) and to the spe-
cific service/business area’s contribution to the general results (m4,18).
CONCLUSIONS: The study suggests that CP’s directors haven’t developed an effec-
tive strategic orientation yet. The actual information system is not able to support
them to manage the changes. As long as CPs’ director develop a strategic orienta-
tion, they could act as agent of change.
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OBJECTIVES: Understand country-specific evidence requirements for the national
reimbursement of orphan products (disease prevalence: 5/10,000) in the UK,
France, Spain, Italy and Germany. METHODS: Qualitative research identified
guidelines for reimbursement submission from each national reimbursement
body. 1–5 orphan product appraisals per country were also reviewed to gain insight
into the application of guidelines. Findings are based only on review of the guide-
lines and selected appraisals. RESULTS: The markets studied do not have reim-
bursement processes specifically for orphan products, however special consider-
ations exist. For example, while direct comparator trials are the preferred sources
of clinical evidence for non-orphan products, in certain instances reimbursement
of orphan products has been granted based on placebo-controlled trials accompa-
nied by indirect treatment comparisons. In England, exemptions are made only for
orphan products which extend survival in patients with short life expectancies. In
Scotland, 62% of decisions on orphan indications have been negative, mostly due to
a lack of robust economic evidence. In Italy, access to orphan products is encour-
aged and 94% of those launched are reimbursed: a lower benefit-risk ratio and
evidence outside randomized controlled trials is accepted for orphan products. In
France, orphan products benefit from fast-track procedures; however no special
evidence considerations are acknowledged. Under AM-NutzenV in Germany, the
medical benefit of orphan products is considered confirmed through the marketing
authorisation; thus orphan submissions require a limited submission document.
Whilst no national practices for orphan products exist in Spain, some regions
implement risk-sharing agreements. CONCLUSIONS: Whilst reimbursement bod-
ies recognize data limitations and provide special considerations for orphan prod-
ucts, processes are not explicit and requirements vary, leading to uncertainty in
the reimbursement evidence requirements. It is therefore important to engage
with appropriate reimbursement bodies to fully determine their specific require-
ments and modify one’s submission to demonstrate an orphan product’s ability to
meet payers’ needs.
PHP111
FACTORS PREDICTING REIMBURSEMENT DECISIONS ON ORPHAN DRUGS IN
EIGHT COUNTRIES
Kanters T, Redekop W, Hakkaart L
Erasmus University Rotterdam, Rotterdam, The Netherlands
OBJECTIVES: The number of orphan drugs has increased vastly over the last years.
However, the reimbursement of orphan drugs remains a black box. The objective of
this study was to examine how much reimbursement decisions are influenced by
disease-related and financial aspects of orphan drugs. METHODS: We examined
publicly available reimbursement decisions for all 11 orphan drugs listed on the
Dutch policy rule in eight countries (Australia, Belgium, Canada, England, Ireland,
New Zealand, Scotland, and Wales). We examined whether the proportion of pos-
itive reimbursement decisions (based on the originally submitted price) depended
on number of eligible patients, treatment costs, budget impact or timing of appli-
cation. Information on these factors were based on the Dutch situation. RESULTS:
For these 11 orphan drugs, 45 reimbursement decisions were publicly available, of
which 12 decisions were positive. In addition, three decisions were positive for only
a subgroup of an indication (infantile Pompe disease) and negative for all other
patients (late-onset Pompe disease). Furthermore, in two cases the orphan drug
was not eligible for reimbursement at the originally submitted price. One decision
was deferred to allow additional data collection. The proportion of positive reim-
bursement decisions decreased as treatment cost per patient increased. A similar
relationship was observed between total budget impact and proportion of positive
reimbursement decisions. The number of eligible patients did not influence the
proportion of positive reimbursement decisions. The proportion of positive deci-
sions was lower for orphan drugs that were added to the policy rule at a later time.
CONCLUSIONS: The proportion of positive reimbursement decisions is lower for
drugs with higher treatment costs or budget impact. Future studies should be
conducted with country-specific explanatory factors. Furthermore, future research
should not only examine the outcomes of reimbursement decisions, but also study
the entire reimbursement process to identify areas of improvement.
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OBJECTIVES: To develop a quantitative process to estimate the probability of a
favorable assessment of additional clinical benefit for a new drug for a chronic
non-life threatening disease in Germany METHODS: A multi-criteria decision pro-
cess was use that included: selection of 7 German decision makers; pre-workshop
questionnaires to identify the most important attributes for the decision and their
relative importance; a workshop to develop levels for the most important attri-
butes, map each attribute level to a value function and identify marginal drug
profiles (drugs just demonstrating ‘additional clinical benefit’); post-workshop es-
timation of weighted scores for each marginal product based on the estimated
values and relative importance of their attribute levels and a logistic regression
model to estimate the probability of an ‘additional clinical benefit’ decision as a
function of the weighted scores; post-workshop questionnaire to validate the lo-
gistic regression model using participant ratings for some hypothetical products.
RESULTS: The most important attributes identified for a determination of ‘addi-
tional clinical benefit’ and their relative importance weights (%) were: robustness of
clinical evidence (29%); incremental efficacy (19%); unmet need (12%); incremental
impact on QOL (10%); availability of alternative treatments (9%); safety of new drug
(9%); burden of disease (5%); availability of other country evaluations (4%); budget
impact (3%). The attribute levels and relative value for a positive decision (0-1) for
the most important attribute, robustness of clinical evidence, were: ‘endpoints
and/or comparators not relevant to patients’ (0); ‘clinical endpoints relevant but
comparators not relevant needing indirect comparisons’ (0.764); and ‘all clinical
endpoints and comparators relevant for patients and payers (1)’. The estimates of
the probability of an ‘additional clinical benefit’ for the hypothetical products using
the logistic regression model had 71% positive predictive value and 85% negative
predictive value when compared to participant decisions for these hypothetical
products. CONCLUSIONS: An MCDA process can provide both a qualitative under-
standing and quantitative estimates of the relative importance, attribute levels,
and value scales of different product attributes that influence a decision of ‘addi-
tional clinical benefit’ in Germany.
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